Building on an existing relationship through Catalyst's Propel Partner Program, Catalyst has been providing installation, ...

Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...

Shares of Catalyst Pharmaceuticals Inc. CPRX shed 2.35% to $21.19 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA ...

In trading on Tuesday, shares of Catalyst Pharmaceuticals Inc (Symbol: CPRX) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $21.1648 per share.

Comparing Catalyst Pharmaceuticals's Short Interest Against Its Peers Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing.

Alternative investment giant CVC has launched its first sector agnostic private equity strategy focused on high-quality and faster growing mid-market businesses, predominantly in Europe.